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To evaluate the GABAA receptor in the autistic brain, we performed 123I-IMZ SPECT in 
patients with ASD.  We compared 123I-IMZ SPECT abnormalities in patients who 
showed intellectual disturbance or focal epileptic discharge on EEG to those in patients 
without such findings. 
 
Subjects and methods:  
The subjects consisted of 24 patients with ASD (mean age, 7.3±3.5years), including 9 
with autistic disorder (mean age, 7.0±3.7years) and 15 with Asperger’s disorder (mean 
age, 7.5±3.2years).  We used 10 non-symptomatic partial epilepsy patients (mean age, 
7.8±3.6years) without intellectual delay as a control group. 
For an objective evaluation of the 123I-IMZ SPECT results, we performed an SEE 
(Stereotactic Extraction Estimation) analysis to describe the decrease in accumulation 
in each brain lobule numerically. 
 
Results 
In the comparison of the ASD group and the control group, there was a dramatic 
decrease in the accumulation of 123I-IMZ in the superior and medial frontal cortex.  In 
the group with intellectual impairment and focal epileptic discharge on EEG, the 
decrease in accumulation in the superior and medial frontal cortex was greater than 
that in the group without these findings.  
 
Conclusion 
The present results suggest that disturbance of the GABAergic nervous system may 
contribute to the pathophysiology and aggravation of ASD, since the accumulation of 
123I-IMZ was decreased in the superior and medial frontal cortex, which is considered to 
be associated with inference of the thoughts, feelings, and intentions of others (Theory 
of Mind).  
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Autistic spectrum disorders (ASD) have various causes, including inherited disease, 
central nervous system infection, brain malformation, chromosomal aberration, and 
other.  Unknown causes account for 80-90% of cases.  The probability that a 
monozygotic twin is autistic when the other twin is autistic is 60-90%, which is 
significantly higher than the probability in dizygotic twins (several percent). [1]  
Therefore, it is thought that genetic factors contribute to the onset of autism even in 
cases with otherwise unknown causes, and considerable effort is being devoted to 
identify the causative gene(s).  
Since Prader-Willi syndrome and fragile X syndrome, which are associated with 
Chromosome 15 or X chromosome disorders, complicate autism in many cases, the 
genes in these chromosomes have recently been considered to be associated with the 
cause of autism. [2],[3]  These chromosomes contain the gene for the γ-aminobutyric 
acid (GABA) receptor.[4]  Cook et al. detected an abnormality in the GABA receptor 
subunit gene on chromosome 15q11–q13 in autistic disorder. [5]   In a genome-wide 
expression profiling study, Gantois et al. found that the differential expression in 
neurons of fragile X knockout mice was limited to only three cDNAs, including the δ 
subunit of the GABAA receptor.[6] 
Over the past few years, in investigations that included only part of the brain, 
reductions in and denaturation of the GABAA receptor have been reported 
neuropathologically in the brains of patients with autism.  Fatemi et al. found that the 
GABA receptor was decreased in the superior frontal cortex (Brodmann's area 9), 
parietal cortex (Brodmann's area 40), and cerebellum. [7]  Oblak et al. found 
significant reductions in the number of GABAA receptors and benzodiazepine (BZD) 
binding sites in the superficial layers of the posterior cingulated cortex and the fusiform 
gyrus, and in the number of BZD binding sites in the deep layers of the fusiform gyrus. 
[8] 
Therefore, it is considered that disturbance of the GABAergic nervous system may 
contribute to the onset of ASD and the complication of epilepsy. 
ASD is frequently complicated with epilepsy and epileptic discharge on 
electroencephalogram (EEG). [9]  With regard to the pathogenesis of epilepsy, a recent 
genetic molecular biology study found abnormality of the GABA receptor in addition to 
abnormality of ion channels involved in membrane permeability, such as those for 
electrolytes.  If an ASD patient has an abnormality of the GABAergic nervous system, 




Recently, 123I-iomazenil (IMZ) single photon emission computed tomography (SPECT) 
has been increasingly used for noninvasive evaluation of the GABAergic nervous system. 
123I-IMZ is a ligand that binds to central benzodiazepine receptors (BZR).  BZR and the 
GABAA receptor form a complex, and therefore we can obtain information about the 
GABA receptor indirectly by 123I-IMZ SPECT. 
To evaluate the GABAA receptor in the autistic brain, we performed 123I-IMZ SPECT in 
patients with ASD.  Furthermore, we compared 123I-IMZ SPECT findings in patients 
with intelligence disturbance or focal epileptic discharge on EEG to those in patients 





2. Subjects:  
The subjects consisted of 24 patients (mean age 7.3±3.5 years, range 2 to 15) with ASD, 
which includes autistic disorder, Asperger disorder, and related conditions in DSM-Ⅳ. 
Nine of the 24 had autistic disorder (mean age 7.0±3.7 years, range 2 to 15) and 15 had 
Asperger disorder (mean age 7.5±3.2 years, range 4 to 11) (Table 1). 
An intelligence test (Wechsler intelligence scale for children third edition: WISC-Ⅲ) was 
performed in all cases; 7 subjects had IQ <70 (IQ 50.9±13.9), 8 had 70≦IQ<85 (IQ 77.5
±3.6), and 9 had IQ ≧85 (IQ 99.6±7.2). 
We classified the 15 patients with IQ <85 as intellectual impairment (mean age 7.5±3.9 
years, range 2 to 15 years) and the 9 patients with IQ≧85 as no intellectual impairment 
(mean age 7.1±2.9 years, range 4 to 11). 
EEG was performed in 18 patients with ASD.  In 6 of these 18 patients (mean age 6.2
±2.7 years, range 4 to 11), focal epileptic discharge was noted on EEG; in the frontal 
region in 4 patients (F4+F8, F3, F3, F3+F7) and in the central region in 2 (C3, C3).  
The only patient who was taking an anti-epileptic drug was diagnosed as autistic 
disorder, and the antiepileptic drug was sodium valproate.  None of the patients were 
taking benzodiazepine drugs. Twelve of these 18 patients (mean age 6.4±3.3 years, 
range 4 to 12) had no epileptic discharge on EEG 
We used 10 non-symptomatic partial epilepsy patients (mean age 7.8±3.6 years, range 
6 to 13) without intellectual delay (IQ 99.8±2.5) or any developmental disorder as a 
control group.  None of the children in the control group showed epileptic discharge in 
the frontal lobe.  Seven of these 10 children used an anti-epileptic drug 
(carbamazepine: 4 patients, phenytoin: 1, sodium valproate: 2).  Furthermore, none of 
the children in the control group had abnormal findings in brain MRI or 
123I-IMZ-SPECT, as assessed by both a pediatric neurologist and a radiologist. 
This study was approved by the Institutional Review Board of our institution, and 
informed consent was obtained from the family members of all of the children after the 





3.  Methods 
After the infusion of 123I-IMZ, radioactivity in the brain cortex reaches a peak at 20 to 
40 minutes.  Therefore, the intracerebral distribution of 123I-IMZ reflects regional 
cerebral blood flow immediately after administration.  Images taken 2-3 hours after 
administration reflect the benzodiazepine receptor distribution, since 123I-IMZ is 
accumulated in BZR for a long time. [10]  Therefore, in this study, late images were 
obtained 180 minutes after the administration of 123I-IMZ at a dose of 167 MBq.  All 
patients were treated with triclofos sodium (Tricloryl; 0.5 ml/kg body weight) for 
sedation one hour before the SPECT measurement. The SPECT measurement was 
conducted with a two-head gamma camera scanner (E.CAM: Toshiba, Tokyo, Japan) 
with a fan beam collimator, a Butterworth filter, and filtered back projection (matrix 
size = 64x64: voxel size = 3.4 mm). 
We needed a method for the objective evaluation of 123I-IMZ SPECT results, which 
would not be influenced by the skill of the reviewer.  Therefore, we performed a 3D- 
Stereotactic Surface Projection (SSP) analysis by iNEUROSTATⓇ (Nihon 
Medi+Physics) for the objective evaluation of 123I-IMZ SPECT results.  After 
stereotactic anatomic standardization, 123I-IMZ accumulation in an individual's 
123I-IMZ SPECT image set was extracted to a set of predefined surface pixels 
(three-dimensional stereotactic surface projection, 3D-SSP), which was used in the 
subsequent analysis.[11] 
 A normal database was previously created by averaging extracted datasets of normal 
adult subjects, and is available for use.  For adults, patients' datasets are individually 
compared with the normal database by calculating a Z-score on a pixel-by-pixel basis, 
and are displayed in 3D-SSP views for visual inspection: Z score=（（average voxel level 
in the control group－voxel level in a patient）/ Control group standard deviation） 
However, in children, a comparable open normal database is not available.  Therefore, 
we used 10 non-symptomatic partial epilepsy patients in our hospital (mean age 7.8 
years). 
In this study, we used iSSP3.5_2tzⓇ(Nihon Medi+Physics) to compare the 3D-SSP 
results in 123I-IMZ SPECT between patients and control subjects.[12]  The extracted 
cortical activity in the patient group was compared to that in the control group using a 
two-sample Student's t-test on a pixel-by-pixel basis. Calculated t values were 
converted to Z values using a probability integral transformation.  We also examined 
whether the presence or absence of intelligence disturbance and focal epileptic 
discharge on EEG influenced the results of 123I-IMZ SPECT. 
After the results in the two groups were compared, we performed SEE (Stereotactic 
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Extraction Estimation) analysis by medi+SEE version2Ⓡ (Nihon Medi+Physics) to 
explain the decrease in accumulation numerically for each brain lobule.[13]  We 
divided the whole brain into segments according to SEE methods (level 3, gyrus level 
classification) and assessed the extent of the abnormal region in each segment. 
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Results (Table 2) 
First, we compared the ASD group (n=24) and the control group. (Figure 1)   There 
was a dramatic decrease in the accumulation of 123I-IMZ in the superior and medial 
frontal cortex.  By an SEE analysis, 29.4% of the left superior frontal gyrus, 23.9% of 
the right superior frontal gyrus and 28.7% of the left medial frontal gyrus showed 
accumulation decreases with Z scores of more than 2.  
Next, we divided the 24 patients with ASD into 2 groups: 15 with intellectual 
impairment (IQ<85) and 9 with no intellectual impairment (IQ≧85).  We compared 
each of these groups with the control group. (Figure 2)  In the group with intellectual 
impairment, there was a dramatic decrease in accumulation in the superior and medial 
frontal cortex.  By an SEE analysis, 39.7% of the left and 25.1% of the right superior 
frontal gyrus showed accumulation decreases with Z scores of more than 2.  In addition, 
26.7% of the left medial frontal gyrus also showed an accumulation decrease with a Z 
score of more than 2. 
In the group with no intellectual impairment, there was no dramatic decrease in 
accumulation in the superior and medial frontal cortex.  By an SEE analysis, only 6.8% 
of the left and 14.8% of the right superior frontal gyrus showed accumulation decreases 
with Z scores of more than 2.  
We directly compared the group with intellectual impairment to the group without 
intellectual impairment. However, this comparison did not show clear decreases in 
accumulation with Z scores of more than 2.  
EEG was performed in 18 patients with ASD.  We divided these 18 patients into 2 
groups: 6 (mean age 6.2±2.7 years, range 4 to 11) with focal epileptic discharge and 12 
(mean age 6.4±3.3 years, range 2 to 11) with no epileptic discharge.  We compared 
each of these groups with the control group. (Figure 3A, 3B)   
In the group with focal epileptic discharge on EEG, there were dramatic decreases in 
accumulation in the bilateral superior and medial frontal cortex and the left inferior 
frontal cortex.  By an SEE analysis, 47.9% of the left and 26.2% of the right superior 
frontal gyrus and 38.9% of the left and 23.9% of the right medial frontal gyrus showed 
accumulation decreases with Z scores of more than 2.  In addition, 24.9% of the left 
middle and 14.6% of the left inferior frontal gyrus showed accumulation decreases with 
Z scores of more than 2. 
The group with no focal epileptic discharge on EEG also showed an accumulation 
decrease in the superior and medial frontal cortex.  By an SEE analysis, 28.8% of the 
left and 22.9% of the right superior frontal gyrus showed accumulation decreases with a 
Z scores of more than 2.  
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We directly compared the group with focal epileptic discharge on EEG to the group 
without focal epileptic discharge on EEG. (Figure 3C)  In the former group, slight 
decreases in accumulation were noted in the superior and medial frontal cortex and the 




5.  Discussion 
In this study we focused on 123I-IMZ SPECT, which can be used to indirectly evaluate 
intracerebral synaptic cleft GABAA receptors to gain a deeper understanding of the 
GABAergic nervous system in ASD. 
In 1979, it was reported that BZR was decreased at focal sites of epilepsy, and a method 
for imaging the distribution of BZR was developed. [14]  The intracerebral distribution 
of BZR in humans has usually been studied by positron emission tomography (PET) 
with [11C] flumazenil (FMZ) as a tracer.  [11C] FMZ is a BZR antagonist. [15]  
However, the use of PET has been limited because not all institutions have this 
capability.  Therefore, as a simpler and easier alternative to PET, SPECT with 123I-IMZ 
as a tracer was developed [16] 
Central benzodiazepine binds to BZR sites located on GABAA receptors or forms a 
conjugated complex with a chloride ion channel, resulting in inhibition of the neural 
network.  Therefore, the BZR status can be used as an index to indicate changes in the 
inhibitory function of the central nervous system. [17]  We think that it may reflect a 
function of the GABAergic nervous system.  However, some limitations must be 
considered before we can evaluate the GABAergic nervous system by IMZ-SPECT.  The 
benzodiazepine (BZD) site is part of the GABA receptor that is separate from the GABA 
site. It is possible that it is influenced by various physio-pathological processes, such as 
neuronal loss leading to a reduced number of GABA receptors (without any actual 
change in these receptors), changes in the number/density or affinity of GABA receptors, 
or changes in the BZD site alone. 
There are also several potential problems that should be considered when using 
123I-IMZ.  It has been reported that patients on benzodiazepine medication 
(Clonazepam) showed an approximately two-fold higher elimination rate and did not 
show any focal abnormalities of receptor density, and thus were excluded from further 
analysis. [18]   Among the patients in this study, only one was taking an anti-epileptic 
drug (VPA), and none were taking benzodiazepine drugs.  Therefore, anti-epileptic 
drugs were considered to have had little effect on 123I-IMZ SPECT. 
Another problem is the difference in the normal intracerebral distribution of BZR 
between adults and children. [19]  The normal intracerebral distribution of BZR in 
children changes with growth.  There is currently no normal database available for use 
with children, since the existing normal database was created based on results in 
normal adults.  If we use an adult control, we may misdiagnose findings that are 
normal for infants and children as abnormal.  Therefore, we used 10 non-symptomatic 
partial epilepsy patients in our hospital (mean age 7.8 years) without intellectual delay 
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or any developmental disorder as a control group.  Therefore, we think that the present 
decrease in 123I-IMZ accumulation in the superior and medial frontal cortex in ASD 
compared with a pediatric control group is not simply due to their younger age.  
Hashimoto et al. examined sleep EEG findings in autistic children, and reported that 
43% showed epileptic discharges, which were observed mainly in the frontal region.  In 
addition, half of the autistic children with epileptic discharges were complicated with 
epilepsy. [9]  In our study, among ASD patients with focal epileptiform activity on EEG, 
the decrease in 123I-IMZ accumulation in the superior and medial frontal cortex 
compared to the control group was greater than that in the group without focal 
epileptiform activity on EEG.  The region in which accumulation decreased was 
similar to the site where there was substantial focal epileptiform activity on EEG.  
Abnormality of the GABAergic nervous system is considered to be one of several causes 
of the onset of epilepsy in ASD. 
“Theory of Mind” refers to the ability to represent the mental states of others, i.e., their 
thoughts, desires, beliefs, intentions, and knowledge.  Theory of Mind allows a person 
to attribute mental states to oneself and others to explain and predict behavior.  A 
series of neuroimaging studies have examined the neural systems that are engaged 
during representation of the mental states of others relative to conditions that do not 
require such representation.  The results have indicated that the medial prefrontal 
cortex, the temporal-parietal junction, and the temporal poles play important roles in 
representing the mental states of others. [20]   
Wang et al. performed functional MRI in 18 ASD boys to examine the neural circuitry 
that underlies impairments in interpreting communicative intentions in ASD using 
irony comprehension as a test case. [21]   Reduced activity in the medial prefrontal 
cortex and right superior temporal gyrus was observed in children with ASD relative to 
typically developing boys during the perception of potentially ironic vs control scenarios.  
Furthermore, medial prefrontal cortex activity was inversely related to the severity of 
symptoms in children with ASD, such that children with greater social impairment 
showed less activity in this region.  
Fletcher et al. reported a functional neuroimaging study with PET in which they 
examined brain activity in normal volunteers while they performed story 
comprehension tasks that required the attribution of mental states ("theory of mind"). 
[22]   They used H215O as a PET tracer. The resultant brain activity was compared 
with that measured in two control tasks: "physical" stories that did not require this 
mental attribution, and passages of unlinked sentences.  Only the "theory of mind" 
task produced activation in the medial frontal gyrus on the left (Brodmann's area 8).  
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Happé et al. used the same paradigm in five patients with Asperger syndrome. [23]  In 
the “theory of mind” task, while no task-related activity was found in the left medial 
prefrontal region, normal activity was observed in immediately adjacent areas.  These 
findings suggest that a highly circumscribed region of the medial prefrontal cortex is a 
crucial component of the brain system that underlies the normal understanding of other 
minds, and this region is affected in ASD patients.  
In our study, in the ASD group, the accumulation of 123I-IMZ was decreased in the 
medial frontal cortex compared to that in the control group, and ASD patients with 
intellectual impairment showed a greater decrease in the accumulation of 123I-IMZ than 
those without such impairment, which suggests that disturbance of the GABAergic 
nervous system in the medial frontal cortex contributes to the pathophysiology and 
aggravation of ASD. 
We directly compared ASD patients with intellectual impairment to those without such 
impairment.  However, the results did not clearly show accumulation decreases with Z 
scores of more than 2.  Although we believed that there was a clear tendency for ASD 
patients with intellectual impairment to show greater accumulation decreases than 
those without such impairment, this difference was not statistically significant, perhaps 
because both groups had already shown some accumulation decrease.   This suggests 
that the IMZ decrease may be more closely related to autistic features or autism per se, 
rather than intellectual impairment alone. 
This is the first report to demonstrate a decrease in BZR in ASD patients by 123I-IMZ 
SPECT.  A disturbance of the GABAergic nervous system may contribute to the onset 
of ASD because a decrease in the accumulation of 123I-IMZ was observed in the superior 
and medial frontal cortex, which is where we infer the thoughts, feelings, and intentions 
of others (Theory of Mind).  ASD patients with intellectual impairment and focal 
epileptic discharge on EEG showed a greater decrease in the accumulation of 123I-IMZ 
than patients without these findings, which suggests that disturbance of the GABAergic 
nervous system contributes to the aggravation of ASD.   
The present study has some limitations.  First, there were fewer subjects in the control 
group than in the patient group, and this may have influenced the results.  Second, we 
should have evaluated the severity of ASD, such as with the Autism Diagnostic 
Interview-Revised (ADI-R) or the Childhood Autistic Rating Scale (CARS). 
Further studies with a greater number of patients with ASD and control subjects and 
an evaluation of the correlation between the severity of ASD and the decrease in IMZ 
binding will be needed to establish 123I-IMZ SPECT as a specific and accurate tool for 
identifying biological markers of ASD. 
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Figure 1   
Autism spectrum disorders [n=24] vs control  
There was a dramatic decrease in the accumulation of 123I-IMZ in the superior and 
medial frontal cortex.  By an SEE analysis, 29.4% of the left and 23.9% of the right 
superior frontal gyrus and 28.7% of the left medial frontal gyrus showed accumulation 
decreases with Z scores of more than 2.  
 
Surface: Brain surface extraction data (Z score) after comparison of the two groups. 
Level 3: The level of brain classification.  Level 3 is classified in every brain lobule. 





Comparison of the presence and absence of intellectual impairment 
A: IQ<85 [n=15] vs control  
There was a dramatic decrease in accumulation in the superior and medial frontal 
cortex.  By an SEE analysis, 39.7% of the left and 25.1% of the right superior frontal 
gyrus showed accumulation decreases with Z scores of more than 2.  In addition, 26.7% 
of the left medial frontal gyrus also showed an accumulation decrease with a Z score of 
more than 2. 
B: IQ≧85 [n=9] vs control   




Figure 3   
Comparison of the presence and absence of focal epileptiform activity on EEG 
 
A: Patients with focal epileptiform activity on EEG [n=6] vs control  
There was a dramatic decrease in accumulation in the bilateral superior and medial 
frontal cortex and the left inferior frontal cortex. By an SEE analysis, 47.9% of the left 
and 26.2% of the right superior frontal gyrus and 38.9% of the left and 23.9% of the 
right medial frontal gyrus showed accumulation decreases with Z scores of more than 2. 
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In addition, 15.4% of the left middle frontal and 19.3% of the left inferior frontal gyrus 
also showed accumulation decreases with Z scores of more than 2. 
B: Patients with no focal epileptiform activity on EEG [n=12]  vs control  
A decrease in accumulation was also seen in the superior and medial frontal cortex.  By 
an SEE analysis, 28.8% of the left and 22.9% of the right superior frontal gyrus showed 
accumulation decreases with Z scores of more than 2.  
C: Patients with focal epileptiform activity on EEG [n=6] vs Patients with no focal 
epileptiform activity on EEG [n=12] 
Slight decreases in accumulation were seen in the superior and medial frontal cortex 
and the left middle and left inferior frontal gyrus. 
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SD: Standard deviation, IQ: intelligence quotient, EEG: electro encephalography, AED: anti-epileptic drug, VPA: sodium valproate 
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Table 2  SEE analysis in frontal lobe (vs control) 



















Lt 29.4% 39.7% 6.8% 47.9% 28.8%
Rt 23.9% 25.1% 14.8% 26.2% 22.9%
Middle Frontal 
Gyrus  
Lt 3.8% 1.0% 11.5% 24.9% 3.1%
Rt 1.8% 4.7% 3.1% 8.3% 4.1%
Inferior Frontal 
Gyrus  
Lt 2.7% 0.0% 11.9% 14.6% 1.7%
Rt 0.0% 0.7% 6.4% 1.4% 7.1%
Medial Frontal 
Gyrus  
Lt 28.7% 26.7% 7.1% 38.9% 18.0%
Rt 14.0% 9.9% 8.3% 23.9% 11.9%
Orbital Gyrus 
Lt 0.0% 0.0% 0.0% 0.0% 0.0%
Rt 0.0% 0.0% 0.0% 0.0% 0.0%
Rectal Gyrus 
Lt 0.0% 0.0% 0.0% 0.0% 0.0%
Rt 0.0% 0.0% 0.0% 0.0% 0.0%
ASD: autism spectrum disorders, IQ: intelligence quotient, 
Z score
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